I think management overestimated the ADAPT technology and possibly why it still haven't received regulatory approval in the Australia (country of origin), hence they spent a lot of capital on trying to make it successful to get AHZ into the $500M+ MC. Undoubtedly, they took this path for a year too long so it's now only a small revenue maker for AHZ, so they've changed their strategy and re-band to now a TAVR bio-tech start-up with ADAPT maybe able to cover most of their operation and administration cost and since TAVR is in clinical trial this mean a majority of this technology development has been costed except for the clinical trial cost which they can claim at least half on R&D rebate.
- Forums
- ASX - By Stock
- Ann: Notice of Annual General Meeting/Proxy Form
I think management overestimated the ADAPT technology and...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M |
Open | High | Low | Value | Volume |
$15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 760 | $15.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.15 | 388 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 760 | 15.000 |
3 | 2651 | 14.950 |
1 | 100 | 14.800 |
1 | 203 | 14.760 |
1 | 364 | 14.600 |
Price($) | Vol. | No. |
---|---|---|
15.150 | 388 | 1 |
15.300 | 1000 | 1 |
15.350 | 88 | 1 |
15.700 | 277 | 1 |
15.880 | 250 | 1 |
Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online